Oncology Today with Dr Neil Love

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:

Introduction (0:00)Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)Available and Emer...

Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics:

Introduction: Relative Impact of Targeted Treatment (00:00)HER2 Alterations (8:04)KRAS Mutations (24:25)MET Overexpression (30:34)ALK Fusions (32:34)ROS1 Fusions (42:36)RET Fusions (52:00)

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:

Introduction (0:00)Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)Utility of Belantamab Mafodotin ...

Featuring an interview with Dr Ramez Eskander, including the following topics:

Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00)Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53)Comparative eff...

Featuring perspectives from Dr Joshua K Sabari, including the following topics:

Jänne PA et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02 — A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J Thorac Oncol 2025;20(12):1814-28. (0:00)Heymach JV et al. Circulating tumor DNA (ctDNA)...